Neurologix, Inc. (NRGX) - Financial and Strategic Analysis Review

Document Sample
Neurologix, Inc. (NRGX) - Financial and Strategic Analysis Review Powered By Docstoc
					              Neurologix, Inc. (NRGX) - Financial and Strategic Analysis Review

       Reference Code: GDPH62297FSA                                                                                        Publication Date: SEP 2010

       One Bridge Plaza                   Phone            +1 201 5926451                           Revenue           0.0 (million USD)
       Fort Lee, NJ                       Fax              +1 201 5859798                           Net Profit        -13.46 (million USD)
       07024                              Website          www.neurologix.net                       Employees         12
       United States                      Exchange         NRGX [Over The Counter]                  Industry          Pharmaceuticals & Healthcare

      Company Overview
       Neurologix, Inc. (Neurologix) is a clinical stage biotechnology company, engaged in the discovery, development, and
       commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System (CNS).
       The company's treatments are used as alternatives to conventional surgical and pharmacological treatments. Its development
       efforts are focused on gene transfer, for the treatment of Parkinson’s disease. Neurologix's technology, called NLX is undergoing
       its clinical development stages and has completed Phase II clinical trial to treat Parkinson’s disease.

      Key Executives                                                                 SWOT Analysis
                     Name                                  Title                     Neurologix, Inc., SWOT Analysis
       Clark A. Johnson                     Chief Executive Officer                  Strengths                   Weaknesses

       Martin J. Kaplitt, M.D.              Chairman
                                                                                     Sturdy R&D Activities               Negative Margins
       Reginald L. Hardy                    Director
       Cornelius E. Golding                 Director                                 Broad Patent Portfolio              Limited Liquidity Position
       Jeffrey B. Reich, M.D.               Director
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData
                                                                                     Opportunities                       Threats
      Share Data
                                                                                     Strategic Agreements                Cost Containment Pressures
       Neurologix, Inc.
       Share Price (USD) as on 20-Apr-2010                                 0.70      Market Potential-Huntington’s Intense Competition
                                                                          -0.59      Disease
       EPS (USD)
       Market Cap (million USD)                                                 19

       Enterprise Value (million USD)                                           15
                                                                                     Source: Annual Report, Company Website, Primary and Secondary Research
       Shares Outstanding (million)                                             28   GlobalData
       Source: Annual Report, Company Website, Primary and Secondary Research
       GlobalData

      Financial Performance                                                          Recent Developments
                                                                                     Aug 12, 2010         Neurologix Reports Net Loss Of $5.3
                                                                                                          Million For Q2 2010
       
				
DOCUMENT INFO
Description: Neurologix, Inc. (Neurologix) is a clinical stage biotechnology company, engaged in the discovery, development, and commercialization of life-altering gene transfer therapies for serious disorders of the brain and Central Nervous System (CNS). The company's treatments are used as alternatives to conventional surgical and pharmacological treatments. Its development efforts are focused on gene transfer, for the treatment of Parkinson’s disease. Neurologix's technology, called NLX is undergoing its clinical development stages and has completed Phase II clinical trial to treat Parkinson’s disease. Neurologix, Inc. Key Recent Developments Aug 12, 2010 Neurologix Reports Net Loss Of $5.3 Million For Q2 2010 May 13, 2010 Neurologix Reports Net Loss Of $4.3 Million For Q1 2010 Mar 10, 2010 Neurologix Names Clark Johnson As President And CEO Feb 22, 2010 Neurologix Names Reginald Hardy As Director Nov 12, 2009 Neurologix Reports Net Loss Of $4.2 Million For Q3 2009 This comprehensive SWOT profile of Neurologix, Inc. provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better. The profile contains critical company information including, - Business description – A detailed description of the company’s operations and business divisions. - Corporate strategy – Analyst’s summarization of the company’s business strategy. - SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats. - Company history – Progression of key events associated with the company. - Major products and services – A list of major products, services and brands of the company. - Key competito
BUY THIS DOCUMENT NOW PRICE: $125 100% MONEY BACK GUARANTEED
PARTNER GlobalData
GlobalData is an industry analysis specialist, providing business information products and services. GlobalData’s highly qualified team of analysts, researchers, and solution consultants use proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a UK-based company with presence across North America, Europe and Asia Pacific and has a broad product offering that ranges from interactive databases, reports and custom solutions. It is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries. GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries. Sectors and Geographies Covered GlobalData has a broad range of coverage over key market segments. It has a global scope, covering a wide range of countries constituting more than 90% of global revenues in each of the industries it covers. Research Methodology With a large dedicated research and analysis capability, GlobalData employs rigorous primary and secondary research techniques in developing unique data sets and research materials. Its status as an independent research company allows Analysts to conduct trade interviews with key industry players. Access to unique databases of in-house market information further strengthens research and analysis capabilities. Materials are reviewed shaped by an expert panel of leading industry figures and representatives from key players in the relevant industries.